GenomeFrontier, BioCina Partner on DNA for CAR-T Cell Therapy

BioCina Pty Ltd., a global biologics contract development and manufacturing organization (CDMO), formed a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment.

BioCina will support GenomeFrontier with process development and GMP manufacturing for Minicircle DNA and Plasmid DNA. GenomeFrontier will leverage their proprietary virus-free cell and gene engineering platforms and Quantum Engine cell-engineering system to manufacture the CAR-T cell therapy for use in a Phase 1 clinical trial.

BioCina’s CEO Mark Womack, said, “We at BioCina are thrilled to be GenomeFrontier’s CDMO partner for this important cancer treatment program, utilizing both Minicircle and Plasmid DNA, providing us yet another opportunity to showcase our scientific and technical expertise in support of the CAR-T cell therapy product.”

GenomeFrontier’s founder and CEO/CSO, Sareina Wu, said, “We believe that a cancer-free world is not only possible but is more real than ever before, due to major advancements in gene therapy. Therefore, we passionately strive to provide patients with next-generation virus-free gene therapies that are not only advanced and accessible, but also affordable.”